S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
NASDAQ:HSKA

Heska Stock Forecast, Price & News

$163.71
-3.05 (-1.83 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$162.55
Now: $163.71
$167.65
50-Day Range
$123.83
MA: $147.52
$166.76
52-Week Range
$50.00
Now: $163.71
$168.68
Volume51,100 shs
Average Volume63,006 shs
Market Capitalization$1.55 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.65
Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal segment offers Element DC and Element DC5x veterinary chemistry analyzers for blood chemistry and electrolyte analysis; Element HT5 and HemaTrue veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; Element i immunodiagnostic analyzers; Element COAG veterinary analyzers; and IV infusion pumps. It also provides digital radiography hardware and mobile digital radiography products, as well as ultrasound systems; Cloudbank, a Web-based image storage solution; ViewCloud and HeskaView, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; Tri-Heart Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. The company's Other Vaccines and Pharmaceuticals segment offers a line of bovine vaccines; biological and pharmaceutical products for other animal health companies; and various turnkey services comprising research, licensing, production, labeling, and packaging, as well as provides validation support and distribution services. It sells its products to veterinarians through a field organization, a telephone sales force, and third party distributors; and trade shows, print advertising, and other distribution relationships. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is based in Loveland, Colorado.
Heska logo

MarketRank

Overall MarketRank

1.21 out of 5 stars

Medical Sector

801st out of 1,926 stocks

Diagnostic Substances Industry

15th out of 32 stocks

Analyst Opinion: 1.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HSKA
CUSIPN/A
Phone970-493-7272
Employees386

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$122.66 million
Cash Flow$0.98 per share
Book Value$19.72 per share

Profitability

Net Income$-1,470,000.00

Miscellaneous

Market Cap$1.55 billion
Next Earnings Date2/23/2021 (Estimated)
OptionableNot Optionable
$163.71
-3.05 (-1.83 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HSKA News and Ratings via Email

Sign-up to receive the latest news and ratings for HSKA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Heska (NASDAQ:HSKA) Frequently Asked Questions

How has Heska's stock price been impacted by COVID-19 (Coronavirus)?

Heska's stock was trading at $81.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HSKA stock has increased by 100.1% and is now trading at $163.71.
View which stocks have been most impacted by COVID-19
.

Is Heska a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Heska stock.
View analyst ratings for Heska
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Heska?

Wall Street analysts have given Heska a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Heska wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Heska's CEO?

1,448 employees have rated Heska CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Heska's employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Heska's next earnings date?

Heska is scheduled to release its next quarterly earnings announcement on Tuesday, February 23rd 2021.
View our earnings forecast for Heska
.

How were Heska's earnings last quarter?

Heska Co. (NASDAQ:HSKA) issued its quarterly earnings data on Thursday, November, 5th. The medical research company reported ($0.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.20) by $0.37. The medical research company earned $56.64 million during the quarter, compared to analyst estimates of $48.55 million. Heska had a negative net margin of 11.15% and a negative return on equity of 2.29%.
View Heska's earnings history
.

What price target have analysts set for HSKA?

4 Wall Street analysts have issued 12 month price objectives for Heska's stock. Their forecasts range from $59.00 to $163.50. On average, they anticipate Heska's share price to reach $131.13 in the next year. This suggests that the stock has a possible downside of 19.9%.
View analysts' price targets for Heska
or view Wall Street analyst' top-rated stocks.

Who are some of Heska's key competitors?

What other stocks do shareholders of Heska own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heska investors own include Gilead Sciences (GILD), Exxon Mobil (XOM), Netflix (NFLX), Biogen (BIIB), AbbVie (ABBV), Amgen (AMGN), Broadcom (AVGO), Alibaba Group (BABA), Exelixis (EXEL) and Merck & Co., Inc. (MRK).

Who are Heska's key executives?

Heska's management team includes the following people:
  • Mr. Kevin S. Wilson, CEO, Pres & Director (Age 48, Pay $609.3k)
  • Ms. Catherine I. Grassman CPA, Exec. VP & CFO (Age 44, Pay $266.51k)
  • Dr. Nancy Wisnewski, Exec. VP & COO (Age 57, Pay $311.22k)
  • Mr. Steven M. Eyl, Chief Commercial Officer (Age 54, Pay $310.34k)
  • Mr. Christopher D. Sveen, Exec. VP, Chief Admin. Officer, Gen. Counsel & Pres of Diamond Animal Health
  • Mr. Jon Aagaard, Director of Investor Relations
  • Mr. Jason D. Aroesty, Exec. VP of International Diagnostics (Age 45)
  • Daniel J. Pollack, VP of Imaging Operations, Treasurer & Assistant Sec.
  • Ms. Eleanor F. Baker, VP, Gen. Counsel & Sec.
  • Laurie E. Peterson, VP of Heska Des Moines

What is Heska's stock symbol?

Heska trades on the NASDAQ under the ticker symbol "HSKA."

Who are Heska's major shareholders?

Heska's stock is owned by many different retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (0.99%), State of Alaska Department of Revenue (0.07%) and Crossmark Global Holdings Inc. (0.02%). Company insiders that own Heska stock include Bonnie J Trowbridge, Jason A Napolitano, Jason D Aroesty, Kevin S Wilson, Nancy Wisnewski and Scott Humphrey.
View institutional ownership trends for Heska
.

Which institutional investors are selling Heska stock?

HSKA stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have sold Heska company stock in the last year include Bonnie J Trowbridge, Jason D Aroesty, Kevin S Wilson, and Nancy Wisnewski.
View insider buying and selling activity for Heska
or view top insider-selling stocks.

Which institutional investors are buying Heska stock?

HSKA stock was acquired by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, and Crossmark Global Holdings Inc..
View insider buying and selling activity for Heska
or or view top insider-buying stocks.

How do I buy shares of Heska?

Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Heska's stock price today?

One share of HSKA stock can currently be purchased for approximately $163.71.

How big of a company is Heska?

Heska has a market capitalization of $1.55 billion and generates $122.66 million in revenue each year. The medical research company earns $-1,470,000.00 in net income (profit) each year or $0.05 on an earnings per share basis. Heska employs 386 workers across the globe.

What is Heska's official website?

The official website for Heska is www.heska.com.

How can I contact Heska?

Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.